AOD-9604
Also known as · hGH fragment 176-191 analogue · METAOD programme (Metabolic Pharmaceuticals)
- EvidenceClinical
- CategoryGH secretagogue
- Routeoral
- Half-lifen.a.
01 / Dosing schedule
Cited dosing
AOD-9604's pivotal human evidence is the phase 2b OPTIONS obesity trial, and critically it was an oral tablet programme, not the injectable protocol sold online. Dose groups were 0.25 mg, 0.5 mg and 1 mg once daily versus placebo; the trial did not beat placebo and development stopped.
AOD9604 phase 2b OPTIONS obesity trial — oral, once daily
| Phase | Dose & frequency |
|---|---|
| Dose groups | 0, 0.25, 0.5 and 1 mg (0 = placebo) |
| Route | oral tablets |
| Frequency | once per day |
| Primary endpoint | weight loss at 12 weeks vs placebo |
| Randomised treatment period | 24 weeks double-blind; full protocol 32 weeks |
| Population | 536 subjects, BMI 30-45 kg/m2, age 18-65, waist >102 cm (men) / >95 cm (women) |
| Injectable subcutaneous dose | n.a. — no injectable AOD-9604 dose was confirmed from a primary source in this session |
Source indication · Obesity: 536 subjects with BMI 30-45 kg/m2, aged 18-65 (Metabolic Pharmaceuticals phase 2b 'OPTIONS' study)
- Injection frequency
- Once daily, oral, for 24 weeks of randomised treatment within a 32-week protocol.
- Injection sites
- Not applicable — the phase 2b programme was an oral tablet, so no injection site exists in the trial record.
02 / Reconstitution
Reconstitution reference
Not applicable: the phase 2b trial used tablets. Any subcutaneous reconstitution scheme for AOD-9604 has no basis in the trial documentation fetched here.
03 / Overview
Protocol overview
AOD-9604 is a modified C-terminal fragment of human growth hormone (residues 176-191) developed by Metabolic Pharmaceuticals in Australia as an anti-obesity agent. It reached phase 2b and then stopped; it has never been approved anywhere as a weight-loss drug.
The pivotal study, called OPTIONS, enrolled 536 subjects with BMI 30-45 kg/m2 and elevated waist circumference. It randomised them to oral AOD9604 0.25 mg, 0.5 mg or 1 mg once daily, or matching placebo tablets, with weight loss at 12 weeks as the primary endpoint within a 24-week double-blind period.
The single most important honesty point for a dosing page: the milligram amounts that survive in the literature are oral once-daily tablet doses under 1 mg. They are not subcutaneous doses, and the sponsor's own release describes the route as 'oral (tablets)'.
No human elimination half-life and no injection site could be confirmed from a primary source in this session, so both are recorded as n.a. The trial ultimately failed to demonstrate efficacy versus placebo, which is why the programme did not advance to phase 3.
04 / References